Last reviewed · How we verify
Atezolizumab - 21 Day Cycle — Competitive Intelligence Brief
phase 1
Monoclonal antibody
Live · refreshed every 30 min
Target snapshot
Atezolizumab - 21 Day Cycle (atezolizumab-21-day-cycle) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Atezolizumab - 21 Day Cycle TARGET | atezolizumab-21-day-cycle | Pfizer Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Atezolizumab - 21 Day Cycle CI watch — RSS
- Atezolizumab - 21 Day Cycle CI watch — Atom
- Atezolizumab - 21 Day Cycle CI watch — JSON
- Atezolizumab - 21 Day Cycle alone — RSS
Cite this brief
Drug Landscape (2026). Atezolizumab - 21 Day Cycle — Competitive Intelligence Brief. https://druglandscape.com/ci/atezolizumab-21-day-cycle. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab